[HTML][HTML] Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma
PC Iyer, R Dadu, M Gule-Monroe, NL Busaidy… - … for immunotherapy of …, 2018 - Springer
Background Anaplastic thyroid carcinoma (ATC) is a rare but deadly form of thyroid cancer.
Kinase inhibitors kinase inhibitors have shown clinical efficacy in the management of ATC …
Kinase inhibitors kinase inhibitors have shown clinical efficacy in the management of ATC …
Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in BRAFV600E-Mutated Anaplastic Thyroid Carcinoma
JR Wang, ME Zafereo, R Dadu, R Ferrarotto… - Thyroid, 2019 - liebertpub.com
Background: When achieved, complete surgical resection improves outcomes in anaplastic
thyroid carcinoma (ATC). However, most ATC patients present with advanced inoperable …
thyroid carcinoma (ATC). However, most ATC patients present with advanced inoperable …
Real-world experience with targeted therapy for the treatment of anaplastic thyroid carcinoma
Background: Patients with anaplastic thyroid cancer (ATC) have a dismal prognosis, despite
systemic cytotoxic chemotherapy. The objective of this study was to investigate the efficacy …
systemic cytotoxic chemotherapy. The objective of this study was to investigate the efficacy …
Computer-aided detection of brain metastases in T1-weighted MRI for stereotactic radiosurgery using deep learning single-shot detectors
Z Zhou, JW Sanders, JM Johnson, MK Gule-Monroe… - Radiology, 2020 - pubs.rsna.org
Background Brain metastases are manually identified during stereotactic radiosurgery
(SRS) treatment planning, which is time consuming and potentially challenging. Purpose To …
(SRS) treatment planning, which is time consuming and potentially challenging. Purpose To …
Acquired Secondary RAS Mutation in BRAFV600E-Mutated Thyroid Cancer Patients Treated with BRAF Inhibitors
ME Cabanillas, R Dadu, P Iyer, KB Wanland… - Thyroid, 2020 - liebertpub.com
Background: The BRAFV600E mutation is the most common driver mutation in papillary
thyroid cancer (PTC) and anaplastic thyroid cancer (ATC). This mutation is considered …
thyroid cancer (PTC) and anaplastic thyroid cancer (ATC). This mutation is considered …
Preclinical and clinical efficacy of trastuzumab deruxtecan in breast cancer brain metastases
Purpose: Brain metastases can occur in up to 50% of patients with metastatic HER2-positive
breast cancer. Because patients with active brain metastases were excluded from previous …
breast cancer. Because patients with active brain metastases were excluded from previous …
Neoadjuvant selpercatinib for advanced medullary thyroid cancer
Y Jozaghi, M Zafereo, MD Williams… - Head & …, 2021 - Wiley Online Library
Background Targeted kinase inhibitors have been increasingly utilized in the treatment of
advanced medullary thyroid cancer (MTC) over the last decade. Recently, highly potent next …
advanced medullary thyroid cancer (MTC) over the last decade. Recently, highly potent next …
Neoadjuvant selective RET inhibitor for medullary thyroid cancer: A case series
KJ Contrera, MK Gule-Monroe, MI Hu, ME Cabanillas… - Thyroid, 2023 - liebertpub.com
Materials and Methods This retrospective consecutive case series was conducted under
institutional IRB protocol PA-14-1082, by which patient consent was waived. All patients with …
institutional IRB protocol PA-14-1082, by which patient consent was waived. All patients with …
MetNet: Computer-aided segmentation of brain metastases in post-contrast T1-weighted magnetic resonance imaging
Z Zhou, JW Sanders, JM Johnson… - Radiotherapy and …, 2020 - Elsevier
Purpose Brain metastases are manually contoured during stereotactic radiosurgery (SRS)
treatment planning, which is time-consuming, potentially challenging, and laborious. The …
treatment planning, which is time-consuming, potentially challenging, and laborious. The …
Atezolizumab combinations with targeted therapy for anaplastic thyroid carcinoma (ATC).
ME Cabanillas, R Dadu, R Ferrarotto, S Liu… - 2020 - ascopubs.org
6514 Background: ATC is a rare/aggressive cancer with dismal outcome.
Dabrafenib/trametinib is approved for BRAF-mutated ATC but pts eventually develop …
Dabrafenib/trametinib is approved for BRAF-mutated ATC but pts eventually develop …